Pediatric high-grade glioma: Biologically and clinically in need of new thinking

Chris Jones, Matthias A. Karajannis, David T.W. Jones, Mark W. Kieran, Michelle Monje, Suzanne J. Baker, Oren J. Becher, Yoon-Jae Cho, Nalin Gupta, Cynthia Hawkins, Darren Hargrave, Daphne A. Haas-Kogan, Nada Jabado, Xiao Nan Li, Sabine Mueller, Theo Nicolaides, Roger J. Packer, Anders I. Persson, Joanna J. Phillips, Erin F. SimondsJames M. Stafford, Yujie Tang, Stefan M. Pfister, William A. Weiss

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

High-grade gliomas in children are different from those that arise in adults. Recent collaborative molecular analyses of these rare cancers have revealed previously unappreciated connections among chromatin regulation, developmental signaling, and tumorigenesis. As we begin to unravel the unique developmental origins and distinct biological drivers of this heterogeneous group of tumors, clinical trials need to keep pace. It is important to avoid therapeutic strategies developed purely using data obtained from studies on adult glioblastoma. This approach has resulted in repetitive trials and ineffective treatments being applied to these children, with limited improvement in clinical outcome. The authors of this perspective, comprising biology and clinical expertise in the disease, recently convened to discuss the most effective ways to translate the emerging molecular insights into patient benefit. This article reviews our current understanding of pediatric high-grade glioma and suggests approaches for innovative clinical management.

Original languageEnglish (US)
Pages (from-to)153-161
Number of pages9
JournalNeuro-Oncology
Volume19
Issue number2
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Glioma
Pediatrics
Glioblastoma
Chromatin
Neoplasms
Carcinogenesis
Clinical Trials
Therapeutics

Keywords

  • Clinical trials
  • Dipg
  • Genomics
  • Glioma
  • Pediatric

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Jones, C., Karajannis, M. A., Jones, D. T. W., Kieran, M. W., Monje, M., Baker, S. J., ... Weiss, W. A. (2017). Pediatric high-grade glioma: Biologically and clinically in need of new thinking. Neuro-Oncology, 19(2), 153-161. https://doi.org/10.1093/neuonc/now101

Pediatric high-grade glioma : Biologically and clinically in need of new thinking. / Jones, Chris; Karajannis, Matthias A.; Jones, David T.W.; Kieran, Mark W.; Monje, Michelle; Baker, Suzanne J.; Becher, Oren J.; Cho, Yoon-Jae; Gupta, Nalin; Hawkins, Cynthia; Hargrave, Darren; Haas-Kogan, Daphne A.; Jabado, Nada; Li, Xiao Nan; Mueller, Sabine; Nicolaides, Theo; Packer, Roger J.; Persson, Anders I.; Phillips, Joanna J.; Simonds, Erin F.; Stafford, James M.; Tang, Yujie; Pfister, Stefan M.; Weiss, William A.

In: Neuro-Oncology, Vol. 19, No. 2, 01.01.2017, p. 153-161.

Research output: Contribution to journalArticle

Jones, C, Karajannis, MA, Jones, DTW, Kieran, MW, Monje, M, Baker, SJ, Becher, OJ, Cho, Y-J, Gupta, N, Hawkins, C, Hargrave, D, Haas-Kogan, DA, Jabado, N, Li, XN, Mueller, S, Nicolaides, T, Packer, RJ, Persson, AI, Phillips, JJ, Simonds, EF, Stafford, JM, Tang, Y, Pfister, SM & Weiss, WA 2017, 'Pediatric high-grade glioma: Biologically and clinically in need of new thinking', Neuro-Oncology, vol. 19, no. 2, pp. 153-161. https://doi.org/10.1093/neuonc/now101
Jones C, Karajannis MA, Jones DTW, Kieran MW, Monje M, Baker SJ et al. Pediatric high-grade glioma: Biologically and clinically in need of new thinking. Neuro-Oncology. 2017 Jan 1;19(2):153-161. https://doi.org/10.1093/neuonc/now101
Jones, Chris ; Karajannis, Matthias A. ; Jones, David T.W. ; Kieran, Mark W. ; Monje, Michelle ; Baker, Suzanne J. ; Becher, Oren J. ; Cho, Yoon-Jae ; Gupta, Nalin ; Hawkins, Cynthia ; Hargrave, Darren ; Haas-Kogan, Daphne A. ; Jabado, Nada ; Li, Xiao Nan ; Mueller, Sabine ; Nicolaides, Theo ; Packer, Roger J. ; Persson, Anders I. ; Phillips, Joanna J. ; Simonds, Erin F. ; Stafford, James M. ; Tang, Yujie ; Pfister, Stefan M. ; Weiss, William A. / Pediatric high-grade glioma : Biologically and clinically in need of new thinking. In: Neuro-Oncology. 2017 ; Vol. 19, No. 2. pp. 153-161.
@article{f03697a6373b4862ba6f4738f762682f,
title = "Pediatric high-grade glioma: Biologically and clinically in need of new thinking",
abstract = "High-grade gliomas in children are different from those that arise in adults. Recent collaborative molecular analyses of these rare cancers have revealed previously unappreciated connections among chromatin regulation, developmental signaling, and tumorigenesis. As we begin to unravel the unique developmental origins and distinct biological drivers of this heterogeneous group of tumors, clinical trials need to keep pace. It is important to avoid therapeutic strategies developed purely using data obtained from studies on adult glioblastoma. This approach has resulted in repetitive trials and ineffective treatments being applied to these children, with limited improvement in clinical outcome. The authors of this perspective, comprising biology and clinical expertise in the disease, recently convened to discuss the most effective ways to translate the emerging molecular insights into patient benefit. This article reviews our current understanding of pediatric high-grade glioma and suggests approaches for innovative clinical management.",
keywords = "Clinical trials, Dipg, Genomics, Glioma, Pediatric",
author = "Chris Jones and Karajannis, {Matthias A.} and Jones, {David T.W.} and Kieran, {Mark W.} and Michelle Monje and Baker, {Suzanne J.} and Becher, {Oren J.} and Yoon-Jae Cho and Nalin Gupta and Cynthia Hawkins and Darren Hargrave and Haas-Kogan, {Daphne A.} and Nada Jabado and Li, {Xiao Nan} and Sabine Mueller and Theo Nicolaides and Packer, {Roger J.} and Persson, {Anders I.} and Phillips, {Joanna J.} and Simonds, {Erin F.} and Stafford, {James M.} and Yujie Tang and Pfister, {Stefan M.} and Weiss, {William A.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1093/neuonc/now101",
language = "English (US)",
volume = "19",
pages = "153--161",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Pediatric high-grade glioma

T2 - Biologically and clinically in need of new thinking

AU - Jones, Chris

AU - Karajannis, Matthias A.

AU - Jones, David T.W.

AU - Kieran, Mark W.

AU - Monje, Michelle

AU - Baker, Suzanne J.

AU - Becher, Oren J.

AU - Cho, Yoon-Jae

AU - Gupta, Nalin

AU - Hawkins, Cynthia

AU - Hargrave, Darren

AU - Haas-Kogan, Daphne A.

AU - Jabado, Nada

AU - Li, Xiao Nan

AU - Mueller, Sabine

AU - Nicolaides, Theo

AU - Packer, Roger J.

AU - Persson, Anders I.

AU - Phillips, Joanna J.

AU - Simonds, Erin F.

AU - Stafford, James M.

AU - Tang, Yujie

AU - Pfister, Stefan M.

AU - Weiss, William A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - High-grade gliomas in children are different from those that arise in adults. Recent collaborative molecular analyses of these rare cancers have revealed previously unappreciated connections among chromatin regulation, developmental signaling, and tumorigenesis. As we begin to unravel the unique developmental origins and distinct biological drivers of this heterogeneous group of tumors, clinical trials need to keep pace. It is important to avoid therapeutic strategies developed purely using data obtained from studies on adult glioblastoma. This approach has resulted in repetitive trials and ineffective treatments being applied to these children, with limited improvement in clinical outcome. The authors of this perspective, comprising biology and clinical expertise in the disease, recently convened to discuss the most effective ways to translate the emerging molecular insights into patient benefit. This article reviews our current understanding of pediatric high-grade glioma and suggests approaches for innovative clinical management.

AB - High-grade gliomas in children are different from those that arise in adults. Recent collaborative molecular analyses of these rare cancers have revealed previously unappreciated connections among chromatin regulation, developmental signaling, and tumorigenesis. As we begin to unravel the unique developmental origins and distinct biological drivers of this heterogeneous group of tumors, clinical trials need to keep pace. It is important to avoid therapeutic strategies developed purely using data obtained from studies on adult glioblastoma. This approach has resulted in repetitive trials and ineffective treatments being applied to these children, with limited improvement in clinical outcome. The authors of this perspective, comprising biology and clinical expertise in the disease, recently convened to discuss the most effective ways to translate the emerging molecular insights into patient benefit. This article reviews our current understanding of pediatric high-grade glioma and suggests approaches for innovative clinical management.

KW - Clinical trials

KW - Dipg

KW - Genomics

KW - Glioma

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=85019378147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019378147&partnerID=8YFLogxK

U2 - 10.1093/neuonc/now101

DO - 10.1093/neuonc/now101

M3 - Article

C2 - 27282398

AN - SCOPUS:85019378147

VL - 19

SP - 153

EP - 161

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 2

ER -